From generic to biosimilar drugs: why take an innovative pace?
BACKGROUND: The transition of the generic/biotechnology industry to innovation by investing in innovative R&D will enhance business expertise in biopharmaceutical development and manufacturing. The major impact of this evolution is on patient access to treatment and savings for the health care s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2012-12-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/328 |